A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system
Article in Frontiers in Pharmacology (August 2024)
The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.
Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system
Article in Frontiers in Pharmacology (August 2024)
Precision oncology targeting FGFRs: A systematic review on pre-clinical activity and clinical outcomes of pemigatinib
Article in Critical Reviews in Oncology/Hematology (July 2024)